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Numerous studies have indicated a link between the presence of polymorphism in brain-derived neurotrophic factor (BDNF) and
cognitive and affective disorders. However, only a few have studied these effects longitudinally along with structural changes in
the brain. This study was carried out to investigate whether valine-to-methionine substitution at position 66 (val66met) of pro-
BDNF could be linked to alterations in the rate of decline in skilled task performance and structural changes in hippocampal
volume. Participants consisted of 144 healthy Caucasian pilots (aged 40–69 years) who completed a minimum of 3 consecutive
annual visits. Standardized ﬂight simulator score (SFSS) was measured as a reliable and quantiﬁable indicator for skilled task
performance. In addition, a subset of these individuals was assessed for hippocampal volume alterations using magnetic
resonance imaging. We found that val66met substitution in BDNF correlated longitudinally with the rate of decline in SFSS.
Structurally, age-dependent hippocampal volume changes were also signiﬁcantly altered by this substitution. Our study
suggests that val66met polymorphism in BDNF can be linked to the rate of decline in skilled task performance. Furthermore, this
polymorphismcouldbeusedasapredictoroftheeffectsofageonthestructureofthehippocampusinhealthyindividuals.Such
results have implications for understanding possible disabilities in older adults performing skilled tasks who are at a higher risk
for cognitive and affective disorders.
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Introduction
The neurotrophin family is considered recent in the evolu-
tionary scale and has not been identiﬁed in Caenorhabditis
elegans.
1 It has been estimated that nerve growth factor and
brain-derived neurotrophic factor (BDNF) evolved B600
million years ago from a common ancestral gene.
2 However,
unlike nerve growth factor, BDNF has been remarkably
conserved in lower vertebrates and in mammals with B90%
homology between ﬁsh and mammalian BDNF. The extre-
mely high conservation rate in the BDNF gene suggests that
alterations in this gene have not been evolutionarily toler-
ated.
2 For this reason, the occurrence of single-nucleotide
polymorphism(s) (SNPs) in BDNF may lead to signiﬁcant
structural and functional consequences. BDNF binding and
internalization have been shown to have important roles in
neuronal survival, differentiation,
3 axonal path ﬁnding,
4
regulation of dendritic trafﬁcking to post-synaptic densities,
5
protection against neuronal death in the hippocampus
6 and
induction and maintenance of late-phase potentiation.
7
Furthermore, reduced levels of cortical BDNF have been
shown to correlate with the severity of pathology in mouse
models of Alzheimer’s disease (AD).
8 These studies empha-
size the fact that any abnormalities in BDNF would exert
signiﬁcant functional implications on the brain.
The most widely studied polymorphism in BDNF is
val66met substitution (rs6265), which has consistently been
linked to the occurrence of depression in elderly and
adolescents,
9,10 depressive symptoms associated with AD
11
and stroke.
12 Other psychiatric conditions linked to this
substitution include anorexia nervosa,
13 anxiety-related dis-
orders,
14 depressive episodes in bipolar disorder,
15 suicidal
behavior,
16 schizophrenia
17 and introversion.
18
The G-to-A substitution in the coding exon VIII of the BDNF
gene (G196A) leads to substitution of amino-acid valine to
methionine at position 66 of the pro-BDNF protein (val66met).
The prevalence of this substitution has been found to be the
highest in Asia (B43%) and lowest in Sub-Saharan Africa
(B0.5%). In the United States, the prevalence of met carriers
has been reported to be around 18–32%. Interestingly, small
Native-American communities in Arizona show higher pre-
valence of met alleles (40%).
19,20
The val66met substitution occurs in the pro-domain of
the BDNF protein and is thus unlikely to affect the intrinsic
activity of mature BDNF. However, it seems that val66met
substitution alters BDNF processing and thus the outcome of
BDNF-TrkB signaling. It has been suggested that val66met
substitution can alter the rate of activity-dependent BDNF
release by (1) affecting its proper folding and sorting into
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www.nature.com/tpsecretory vesicles and/or (2) reducing its intracellular distribu-
tion: Within the Golgi apparatus, BDNF can be sorted into
regulated (activity dependent) or constitutive secretory path-
ways. Sortilin, a member of the vacuolar protein sorting 10
family, is highly enriched in the Golgi apparatus and has an
important role in BDNF processing.
21 Through binding to the
pro-domain region of BDNF, sortilin has an important role in
sorting BDNF into the regulated secretory pathway. The
occurrence of val66met substitution in this region leads to a
signiﬁcantdecreaseinBDNFinteractionwithsortilin
21thereby
mis-sorting of BDNF into the constitutive secretory instead of
theregulatedsecretorypathway (Figure 1).Inneurons,BDNF
is not exclusively synthesized in the somata. It has been
shown that fragments of BDNF mRNA are transported from
cell body to dendrites for local synthesis.
22 BDNF gene
expression is achieved by formations of two types of BDNF
mRNA,thosewith short30 untranslated region and otherswith
long 30 untranslated region. The long 30 untranslated region of
the BDNF mRNA is transported to the dendrites, whereas the
short 30 untranslated region remains within the cell body.
23 It
has been suggested that by reducing interaction with translin,
that is, an mRNA-binding protein, G-to-A substitution in the
BDNF gene leads to failed translocation of BDNF mRNA to
dendrites,
24 thus reducing its intracellular distribution.
Owing to the critical role of BDNF in synaptic plasticity
particularly in the hippocampus and the signiﬁcant conse-
quences of val66met substitution on BDNF processing and
intracellular distribution, we asked whether this polymorphism
can alter the rate of decline in skilled task performance along
with changes in the hippocampal volume in the absence of
any neurological or cognitive disorders.
Multiple studies have suggested that abnormalities in
production,transportandsignalingofBDNFhaveasigniﬁcant
role in affective disorders.
25 Volumetric brain alterations
particularly in the hippocampus have also been linked to
BDNF polymorphism.
26 Using a meta-analysis of 399 healthy
individuals, Hajek et al.
26 reported a signiﬁcant reduction in bi-
lateral hippocampal volume in met carriers. Furthermore,
Cathomas et al.
27 studied the relationship between multiple
SNPs on the BDNF gene and verbal episodic memory. From
55 SNPs studied, only val66met polymorphism correlated,
showing poorer performance in met carriers.
28 However, no
study has investigated the correlation between skilled task
performanceinhealthyindividualsandBDNFpolymorphisms.
Such information could help us in understanding the
complex physiology of cognitive and affective alterations
associatedwithnormalaginginolderindividualsattemptingto
perform skilled tasks such as driving, aviation or operating
machinery.
This study was carried out to investigate whether val66met
substitution in BDNF can (1) predict the rate of decline in
performance of skilled tasks, (2) lead to structural alterations
in the hippocampus and (3) alter the pattern of relationship
between aging and hippocampal volume. To address these
questions, we investigated the rate of decline in the skilled
task of piloting an aircraft as determined by a standardized
ﬂight simulator score (SFSS). Standard ﬂight simulation is a
reliable and highly quantiﬁable method for measuring execu-
tive functions that are dependent on several aspects of
cognition, in particular memory and attention, shown by a
signiﬁcantcorrelation betweenSFSSandcognitionmeasured
by CogScreen-AE.
29,30
Figure 1 Schematic representation of possible mechanism by which val66met substitution in BDNF leads to failed activity-dependent release of BDNF or reduced
intracellular transport.Val66metsubstitutionchangesthedynamicsof interactionbetweenBDNFandtwoimportantproteins:(1) Sortilin,isinvolvedin intracellular sortingand
pro-neurotrophin signaling. Val66met substitution leads to reduction of BDNF interaction with this protein, which results in mis-sorting into the constitutive secretory pathway
instead of activity-dependent release. (2) Translin is a highly conserved protein involved in mRNA transport. An exon found in all BDNF mRNA splice variants contains a
speciﬁc translin-binding region, which is essential for appropriate BDNF mRNA dendritic targeting. It has been shown that Val66met substitution diminishes BDNF mRNA
interaction with translin, which leads to reduced translocation of BDNF mRNA to dendrites.
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Translational PsychiatryMaterials and methods
Participants. Participants included 144 Caucasian pilots
who completed a minimum of 3 annual visits (Table 1) as part
of the ongoing longitudinal Stanford/VA Aviation Study,
approved by the Institutional Review Board of Stanford
University. After complete description of the study to the
subjects, written informed consent was obtained. Enrollment
criteria included age older than 40 years, current Federal
Aviation Administration medical certiﬁcate and currently
ﬂying. The participants were either recreational pilots,
certiﬁed ﬂight instructors or civilian air-transport pilots.
Upon enrollment, participants were assigned to one of
three levels of expertise based on their Federal Aviation
Administration proﬁciency rating: (1) least expertise: VFR
(qualiﬁed to ﬂy under visual ﬂight rules only); (2) moderate
expertise: IFR (also qualiﬁed to ﬂy under instrument ﬂight
rules); and (3) most expertise: CFII or ATP (certiﬁed ﬂight
instructor for IFR students or rated for ﬂying air-transport
planes). Each rating requires progressively more advanced
training and more hours of training.
31 Participants were
healthy as determined by their regular physical and mental
examinations performed by trained physicians. The absence
of cognitive impairment was conﬁrmed by CogScreen-AE,
that is, a computerized battery for screening and monitoring
cognitive abilities relevant to ﬂying.
32
Flight simulation. Standard ﬂight simulation enabled us to
investigate the ability to navigate an aircraft in a quantiﬁable
and reproducible manner.
33 We used a Frasca 141 ﬂight
simulator (Urbana, IL, USA), which simulates ﬂying a small
single-engine aircraft. Each individual went through six
practice sessions and a 3-week break before the ﬁrst
baseline visit. The baseline visit and each visit thereafter
consisted of morning and afternoon ﬂights, 75-min in duration
each, during which pilots had to face ﬂight scenarios with
emergency situations such as engine malfunctions and/or
incoming air trafﬁc. For each subsequent ﬂight, several
components were randomly varied and multiple versions of
the ﬂight scenario were presented to reduce learning of
speciﬁc maneuvers and air trafﬁc control messages. The
scoring system produced 23 variables that measured a
combination of the reaction time (in seconds) and deviations
from ideal positions (altitude in feet, heading in degrees and
airspeed in knots).
33 Standardized Z-scores were computed
to match different measurements. In addition, an overall ﬂight
performance summary score, that is, SFSS was computed.
The scores collected represent the accuracy of executing
the air trafﬁc control commands, trafﬁc avoidance, time to
detect engine emergencies and executing a visual approach
to landing. The primary measure of the outcome was the
average rate of change per year in overall SFSS as deter-
mined by the slope of SFSS. Each ﬂight simulation was
followed by 40–60min battery of cognitive tests including
CogScreen AE.
32 These tests were repeated annually.
Genotyping. Blood and saliva samples were collected
during the ﬁrst visit. We used an Illumina Bead Array
platform (Illumina, San Diego, CA, USA) for high-
throughput multiplexed SNP genotyping using Human 610
Quad gene chip. The system uses a high-density BeadArray
technology in combination with an allele-speciﬁc extension,
adapter ligation and ampliﬁcation assay protocol.
34 For
quality control, Ilumina’s BeadStudio Software (version 3.1)
was used to validate the genotypes. Golden Helix SNP and
Variation Suite (SVS Version 7.2.2, Bozeman, MT, USA)
software was used for the analysis. As ApoE polymorphism
markers were not present on HumanHap 650Y chip, a
sample of the DNA was separately used for ApoE alleles
determination,
35 which led to successful genotyping in 98.6%
of participants.
Imaging. Around one-third of participants (43 individuals)
underwent structural magnetic resonance imaging (MRI)
neuroimaging. From these, 65% (28 individuals) returned
1–2 times for follow-up imaging. The average time lag
between the baseline simulator visit and the ﬁrst MRI scan
was 3.85 years (s.d.¼3.0 years).
The MRI data were acquired at the Veterans Affairs Palo
Alto Health Care System on a 1.5-T (General Electric Medical
Systems, Milwaukee, WI, USA) MRI scanner. The following
structural MRI sequences were performed on all participants
using a standard head coil: (1) a spin-echo, sagittal localizer
two-dimensional sequence of 5-mm thick slices; (2) a proton
density and T2-weighted spin-echo MRI, repetition time/echo
time1/echo time2¼5000/30/80ms, 51 oblique axial 3mm
slices covering the entire brain and angulated parallel to the
long axis of the hippocampal formation (1.00 1.00mm
2 in
plane resolution); and (3) three-dimensional spoiled gradient
recalled acquisition in the steady state (GRASS) MRI of the
entire brain, repetition time/echo time¼9/2ms, perpendicular
to the long axis of the hippocampus.
The volume of the hippocampus was determined using
high-dimensional brain warping software (Surgical Navigation
Technologies, Louisville, CO, USA). The Surgical Navigation
Technologies method has been validated and compared with
manual tracing of the hippocampus before (left: r¼0.92; right:
r¼0.91; n¼60).
36 This method, originally developed by
Table 1 Demographic information
Parameter Met carriers
(n¼55)
Non-met
carriers (n¼89)
Age range (years) 42–69 40–69
Age (mean±s.d.) 56.8±0.9 57.1±0.9*
Education range (years) 13–20 12–20
Education (mean±s.d.) 17±0.2 17±0.2**
Apoe4 (%) 21 (38.0%) 55 (62.0%)
Females (%) 7 (7.9%) 15 (6.0%)
% Aviation expertise rating 25.4/58.2/16.3% 22.4/49.4/28.0%
VFR/IFR/CFII-ATP
a
Log hours range 310–13000 310–13990
Log hours (mean±s.d.) 1913.8±2454 2717.2±2845
Abbreviations: BDNF, brain-derived neurotrophic factor; CFII/ATP, certiﬁed ﬂight
instructor/air transport planes; IFR, instrumentﬂightrules; VFR, visualﬂight rules.
*P¼0.7936.
**P¼0.6319.
The homozygous (met/met) and heterozygous (val/met) haplotypes of the BDNF
rs6265 polymorphism were both included as met carriers.
aIFR, allowed to ﬂy
using instruments for accurate navigation after at least 40h of training. CFII/ATP,
certiﬁed to ﬂy air-transport planes. VFR, ﬂying under visual conditions for pilots
whenﬁrstgetalicense andarerestricted toﬂyingonlyingoodvisibilityconditions.
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37 has been used in numerous studies on
AD,
38,39 aging
36,40,41 and schizophrenia.
42 The Surgical
Navigation Technologies semi-automated technique involves
manual placement of global and hippocampal landmarks,
followed by automated atlas mapping. In this study, global
landmarks were placed at external boundaries of the brain
image (by manually adjusting the angle and dimension of a
three-dimensional proportional box to fully enclose the brain).
Next, 22 local landmarks were placed at the boundaries of the
hippocampus: 1 at the head, 1 at the tail and 4 per image (that
is, at the superior, inferior, medial and lateral boundaries) on 5
equally spaced images perpendicular to the long axis of the
ipsilateral hippocampus. The automated hippocampal map-
ping algorithm applied a coarse transformation followed by a
ﬁne and ﬂuid transformation to match the individual image to a
templatebrain.Theﬁnaloutputincludednumericalvolumesof
the right and left hippocampi. In this study, we report total
hippocampal volumes, normalized to each subject’s total
intracranial volume.
Statistical analyses. The primary outcome for skilled task
performance was SFSS.
31 The average rate of change in
SFSS was computed by calculating the slope of linear regres-
sion between SFSS and the number of three consecutive
annual visits yielding a ﬁtted slope. The analysis of variance
and Student’s t-tests were used to test the difference among
met positive (met/val and met/met) and met negative (val/val)
groups. A P-value o0.05 was considered signiﬁcant.
Results
Demographic characteristics. A total of 144 individuals
underwent 3 consecutive annual ﬂight simulations. Of these,
55 (38.2%) were met carriers (met/val or met/met) and
89 (61.8%) were non-met carriers (val/val). The prevalence
of met carriers was close to demographics reported in
healthy individuals.
43 As shown in Table 1, met carriers and
non-met carriers were demographically similar. No signiﬁ-
cant differences were found in age and education levels
between the two groups (Table 1). Both groups had average
of 17 years of education. ApoE genotyping showed that
52% of the participants were ApoE33, 25% ApoE34, 16.6%
ApoE23, 2.77% ApoE44, 1.38% ApoE22 and 0.69% were
ApoE24. We found no signiﬁcant effects of ApoE4 alleles on
the rate of decline of SFSS (t¼ 0.673; P¼0.5020, d.f.¼140)
and hippocampal volume (t¼1.534, P¼0.1286, d.f.¼84).
Standard ﬂight simulator score. Only the data derived
from the ﬁrst three consecutive annual visits were used for
this part of study. The effect of polymorphisms in BDNF
was investigated by quantifying the rate of decline in SFSS
during three consecutive annual visits using a linear regres-
sion. The average rate of decline in SFSS over the next
2 years was signiﬁcantly higher in met carriers than in
non-met carriers (met carriers¼ 0.109±0.134 (n¼55),
non-met carriers¼ 0.036±0.165 (n¼89), F¼7.696,
P¼0.0060) (Figure 2).
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Figure 2 The slope of the SFSS in individuals with and without val66met substitution. As shown, we found a signiﬁcant (ANOVA, F¼7.696, P¼0.0060) reduction
in the slope of ﬂight simulator score in met carriers (mean±s.d., slope¼ 0.110±0.135, n¼55) compared with non-met carriers (slope¼ 0.036±0.165, n¼89) during
the ﬁrst 2 years of follow-up.
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were found in mean log hours of ﬂight between met and non-
met carriers (met carriers¼1913.7±2454h; non-met carriers¼
2717.2±2845h, t-value¼1.733, P¼0.0852, d.f.¼142). To
further test the possible effects of experience on the results,
we compared a subgroup of individuals with very similar log
hours (met carriers¼559.9±184.81h, non-met carriers¼
589.77±197.77h). Our investigation showed a signiﬁcant
difference (P¼0.0043, t-value¼2.974, d.f.¼56) in the
average rate of decline in SFSS for met carriers compared
with non-met carriers, indicating that the difference in the
slope of the SFSS was not signiﬁcantly inﬂuenced by ﬂight
experience.
Hippocampal volume. The total volume of the entire
hippocampus (right plus left) normalized to the total
intracranial volume was quantiﬁed in one-third of individuals
during the course of the study.
Cross-sectional analysis. The total volume of the hippo-
campus was compared between met and non-met carriers.
We found no signiﬁcant effects of val66met substitution on
the average hippocampal size for all visits (met-carriers¼
5.042±0.552cm
3, n¼19, non-met carriers¼5.026±0.487cm
3
n¼24, F¼0.047, P¼0.8290). We also investigated the link
between hippocampal volume and SFSS and found no
signiﬁcant correlation between the two parameters
(r¼ 0.101, P¼0.346), which was not affected by BDNF
polymorphism (met carriers, r¼ 0.058, P¼0.7290, non-
met carriers r¼ 0.117, P¼0.4140).
It has been shown that there is a negative correlation
between hippocampal volume and age in healthy indivi-
duals.
44 The question was raised whether val66met substitu-
tion can alter the pattern of relationship between hippocampal
volume and age. Although we found no signiﬁcant correlation
between the age at MRI and the volume of hippocampus in
non-met carriers (r¼ 0.178, P¼0.2639), a signiﬁcant
negative correlation was detected between the two among
met carriers (r¼ 0.447, P¼0.0150). Furthermore, the slope
of the age-related decline in hippocampal volume in met
carriers (slope¼ 0.038) was two folds higher than that in
non-met carriers (slope¼ 0.016) (Figure 3). Our results also
showed that atrophy of the hippocampus became signiﬁcant
after theage of65years.Unlike non-met carrierswho showed
no difference in hippocampal volume before and after the age
of 65 years, we found a signiﬁcant shrinkage in hippocampal
volume among met carriers after the age of 65 years
(Figure 4).
Longitudinal analysis. Around 65% (n¼28) of participants
who underwent MRI, returned an average of 4.36±2.78
years later for follow-up imaging. The slope of hippocampal
volume alterations for each individual was computed. The
average slope of hippocampal volume alterations was
quantiﬁed longitudinally among met carriers (n¼12) and
non-met carriers (n¼16), even though the follow-up interval
was not consistent. We found no signiﬁcant effects of
val66met substitution on the rate of decline in hippo-
campal volume (r¼ 0.089, P¼0.6500, met carriers¼
 0.105±0.124 and non-met carriers¼ 0.084±0.118).
Discussion
In this study, we found that val66met substitution in BDNF
could predict the rate of decline in skilled task performance in
middle-aged and older healthy individuals. Furthermore, the
rate of decline in hippocampal volume could be signiﬁcantly
affected by this substitution. These results are consistent with
a signiﬁcant reduction in hippocampal volume after the age of
65 years in met carriers as compared with non-met carriers,
reported here.
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Figure 3 The total volume of the hippocampus (both left and right) in individuals with and without val66met substitution. No signiﬁcant differences were found in the
size of the hippocampus, before and after 65 years in non-met carriers (before 65¼100.0±9.63 and after 65¼100.556±10.265: F¼0.031, P-value¼0.8610). However,
there was a signiﬁcant reduction in the size of the hippocampus in met carriers after the age of 65 years (before 65¼104.654±9.938 and after 65¼90.918±6.522,
F¼17.53, P-value¼0.0001). As the result, we found a signiﬁcant difference in the size of the hippocampus after the age of 65 years between met carriers and non-met
carriers (F¼7.207, P-value¼0.014). The number of individuals in their sixth, seventh and eighth decades of life were 15, 15 and 6 among met carriers and 19, 26 and 5
among non-met carriers, respectively.
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Translational PsychiatryOur ﬁnding of a two-fold increase in the rate of decline in
SFSS among met carriers during the ﬁrst 2 years of follow-up
is consistent with the poorer performance and functioning of
met carriers described by Egan et al..
45 The negative effect of
val66met substitution on the hippocampus and synaptic
activity has been supported by decreased levels of N-acetyl-
aspartate, an intracellular marker for neuronal and synaptic
structural integrity.
46 Furthermore, it has been shown that met
carrier individuals show lower hippocampal activity than do
non-met carriers during encoding and retrieval activities.
47
This is supported by a number of studies reporting 11–15%
reduction in the volume of hippocampus in healthy individuals
with val66met substitution.
48–52 The effect of age on
hippocampal volume in met carriers has also been described
inassociationwithchangesintheamygdala.
53Ourresults are
also in concordance with studies that showed no effects of
val66met substitution on hippocampal volume in younger
adults.
47 Interestingly, val66met substitution leads to lower
scores in episodic memory in schizophrenic patients when
compared with their healthy relatives.
54 Finally, as already
noted, BDNF abnormalities have been associated with
affective abnormalities, which in turn might affect motivation
and performance on cognitive tests and skilled tasks.
We did not ﬁnd a signiﬁcant correlation between SFSS
and hippocampal volume in our healthy participants. This
could be due to two reasons: (1) executive functioning is not
solely dependent on the hippocampus. Multiple other brain
structures and circuits have vital roles in this function and
(2) measurements of hippocampal volume and SFSS, for
each individual, were determined at different intervals, which
would make it difﬁcult to detect a signiﬁcant correlation.
Although the direct consequences of val66met substitution
on BDNF levels remain to be clariﬁed, there are a number of
studies that suggest molecular mechanisms by which it could
lead to a more severe decline in executive function and
reduced hippocampal volume. Postmortem examination of
the parietal cortex of AD patients has shown 470% decrease
in BDNF mRNA
55 and 40% decrease in pro-BDNF levels.
56
The role of met alleles on cognition in AD has been
controversial. It has been reported that the frequency of A
alleles (met) in a Japanese AD population was lower than that
of controls by 5%.
57 In the Mainland Chinese Han population,
although a similar frequency of A alleles was found among AD
and controls, they reported a higher frequency of A alleles in
ApoE4 female carriers with AD.
58 However, multiple studies
have failed to ﬁnd higher frequency of A alleles in AD.
59–62
These controversial results might be explained by additional
polymorphism(s)thatmayhavearoleintheoccurrenceofAD.
One example is the C270T polymorphism in the non-coding
area of the BDNF gene, which has been linked to a higher risk
of AD in a Japanese population.
63 In addition, the presence of
several polymorphisms might have synergic effects on the
occurrence of cognitive dysfunction. As mentioned above,
Bian et al.
58 found a higher frequency of val66met substitution
in AD patients only in female ApoE4 carriers subgroup.
Our ﬁnding of the relationship between decline in skilled
task function and val66met polymorphism may have impor-
tant implications for intervention. BDNF has a major role in
activity-dependent plasticity in the hippocampus.
64,65 Indeed,
BDNF null mice show pronounced synaptic fatigue in CA1
synapses during high-frequency stimulation, reduced number
of docked vesicles and decline in synaptic markers in this
area.
66 Accordingly, BDNF gene delivery has been shown to
reverse neuronal atrophy and cognitive deﬁcits in aged
primates and rodent models of AD.
67 Furthermore, BDNF
knockout mice show decreased serotonergic axonal term-
inals,reducedlevelsof5-HTanditsmetabolite(5-HIAA)inthe
hippocampus
68 and increased depression-like behaviors.
69
As val66met polymorphism leads to decreased levels of
activity-dependent BDNF release,
45 strategies to therapeuti-
cally increase BDNF levels including gene therapy and/or the
use of small molecules binding to NTRK2 receptors
70 might
have successful outcome in treating depression and
its associated cognitive deﬁcits than selective serotonin
reuptake inhibitors (SSRIs) that would target one particular
system. There is already evidence that different anti-
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Translational Psychiatrydepressive therapies including antidepressants,
71 electro-
convulsive therapy
72 and repetitive transcranial magnetic
stimulation
73 have all shown to increase BDNF levels in
animalmodelsofdepression.Thus,thereisthepossibilitythat
further research in therapeutics might lead to better treat-
ments for cognitive and affective disorders.
There are a number of limitations to this study. First, for
quantiﬁcation of skilled task performance and decline in
SFSS, we followed the participants for three consecutive
annual visits. There is no doubt that much longer follow-ups
andbiggersamplessizearerequiredtobetterdeﬁnethetrend
and conﬁrm the link with val66met polymorphism. Second,
only about a third of individuals enrolled in this study had
neuroimaging for hippocampal volume alterations. Similar to
theﬁrstpoint,largersample sizeandmeasurementinmultiple
consecutive annual visits are required to conﬁrm our ﬁndings.
Having a larger group would help us to better determine the
role of other factors such as gender, ethnicity, presence of
other polymorphisms and expertise on the effects of val66met
substitution on both cognition and brain structural changes
that may impact SFSS.
Testing executive function in this study was performed
using a ﬂight simulator. Although the result of this study might
have some implication for performance in pilots, it may also
reﬂect age-dependent alterations in executive functions in the
general public performing any skilled tasks that involve
working with complex machinery. Thus, we anticipate the
need of a larger longitudinal study using additional means
of simulations.
In conclusion, we found that the val66met substitution was
able to predict the rate of regression in SFSS and may be
considered as a tool to evaluate the longitudinal decline in
cognitive functioning of healthy individuals. Furthermore, it
seems to modify the nature of the relationship between age
and hippocampal volume. Careful genetic and neurochemical
studies of BDNF may eventually lead to therapeutic interven-
tions of beneﬁt to older adults with cognitive and affective
disorders.
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